Roche NimbleGen and Affymetrix Expand Licensing Agreement

Madison, (PresseBox) - Roche NimbleGen Inc., a company of Roche Applied Science, and Affymetrix Inc. announced that they have expanded the terms of the license to a number of Affymetrix patents originally granted in October 2006. The expanded license now provides certain diagnostic rights for array-based DNA copy number analysis and array-based resequencing in addition to covering the manufacture, use and sale of nucleic acid microarrays and related products and services in the research field. Financial details of the expanded license were not disclosed.

Roche NimbleGen is a leading innovator, manufacturer and supplier of a proprietary suite of DNA microarrays, consumables, instruments and services. Roche NimbleGen uniquely produces high-density arrays of long oligo probes that provide greater information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation. The improved performance is made possible by Roche NimbleGen s proprietary Maskless Array Synthesis (MAS) technology, which uses digital light processing and rapid, high-yield photochemistry to synthesize long oligo, high-density DNA microarrays with extreme flexibility. For more information about Roche NimbleGen, please visit the company s website at www.nimblegen.com.

Press releases you might also be interested in

Weitere Informationen zum Thema "Biotechnology":

Neue Tools für Deep Learning und autonomes Fahren

Ma­thWorks stellt Re­lea­se 2018a (R2018a) mit ei­ner Rei­he neu­er Funk­tio­nen in MAT­LAB und Si­mu­link vor. Dar­un­ter fal­len u.a. die Pre­dic­ti­ve Main­tenan­ce Tool­box zum Ent­wer­fen und Tes­ten von Al­go­rith­men für die Zu­stands­über­wa­chung und Pre­dic­ti­ve Main­tenan­ce und das Ve­hi­c­le Dy­na­mics Block­set für die Mo­del­lie­rung und Si­mu­la­ti­on von Fahr­zeug­dy­na­mik in ei­ner vir­tu­el­len 3D-Um­ge­bung.

Weiterlesen

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.